FLT4 Antikörper

Produktnummer ABIN1589703

Zitiert in 1 Publikation. Der Maus Monoklonal anti-FLT4 Antikörper (Klon 9D9) (ABIN1589703) detektiert spezifisch FLT4 in WB, IHC und ELISA. Dieser Antikörper reagiert spezifisch mit Proben aus Human.

Kurzübersicht für FLT4 Antikörper (ABIN1589703)

Target: FLT4 (Fms-Related Tyrosine Kinase 4 (FLT4))

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser FLT4 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), Immunohistochemistry (IHC), ELISA

Klon: 9D9

Produktdetails anti-FLT4 Antikörper

Verwendungszweck: VEGFR-3/FLT-4 antibody

Spezifität: Recombinant human soluble VEGFR-3/FLT-4

Kreuzreaktivität (Details): The antibody will detect native human VEGFR-1/Flt-1 in ELISA experiments, WB, IF and IP.

Produktmerkmale: Chromosomal location: 5q35.3
This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified recombinant human Vascular Endothelial Growth Factor Receptor 3 (recombinant human VEGFR-3/FLT-4) extracellular domain.

Aufreinigung: Protein-G affinity chromatography

Immunogen: Recombinant human soluble VEGFR-3/FLT-4

Isotyp: IgG1

Anwendungsinformationen

Applikationshinweise: ELISA: Use at 1-5 μg/mL, Western Blot: Use at 1-5 μg/mL, IF/ IHC: Use at 1-10 μg/mL.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Lyophilized

Rekonstitution: Centrifuge vial prior to opening. Reconstitute in sterile water to a concentration of 0.1-1.0 mg/mL.

Buffer: PBS

Handhabung: Centrifuge vial prior to opening.

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: The lyophilized antibody is stable for at least 2 years at -20°C. After sterile reconstitution the antibody is stable at 2-8°C for up to 6 months. Frozen aliquots are stable for at least 6 months when stored at -20°C. Addition of a carrier protein or 50% glycerol is recommended for frozen aliquots.

Haltbarkeit: 24 months

Referenzen für anti-FLT4 Antikörper (ABIN1589703)

Rohringer, Holnthoner, Hackl, Weihs, Rünzler, Skalicky, Karbiener, Scheideler, Pröll, Gabriel, Schweighofer, Gröger, Spittler, Grillari, Redl: "Molecular and cellular effects of in vitro shockwave treatment on lymphatic endothelial cells." in: PLoS ONE, Vol. 9, Issue 12, pp. e114806, (2014) (PubMed).

Details zu FLT4

Target: FLT4 (Fms-Related Tyrosine Kinase 4 (FLT4))

Andere Bezeichnung: VEGFR-3/FLT-4

Hintergrund: Vascular endothelial growth factor receptor-3, FLT4, PCL, LMPH1A, VEGFR3, fms-related tyrosine kinase 4,VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk 1) and VEGFR-3 (FLT-4) belong to the class III subfamily of receptor tyrosine kinases (RTKs). All three receptors contain seven immunoglobulin-like repeats in their extracellular domains and kinase insert domains in their intracellular regions. The expression of VEGFR-1 to -3 is almost exclusively restricted to hematopoietic precursor cells, vascular and lymphatic endothelial cells and to the monocyte/macrophage lineage. These receptors play essential roles in vasculogenesis, hematopoiesis, angiogenesis and lymphangiogenesis. The VEGFR-3 cDNA encodes a 1298 amino acid (aa) residue precursor protein with a 24 aa residue signal peptide. Mature VEGFR-3 is composed of a 751 aa residue extracellular domain, a 22 aa residue transmembrane domain and a 482 aa residue cytoplasmic domain. Both VEGF-C and VEGF-D have been shown to bind and activate VEGF R3 (Flt-4). The Flt-4 gene is widely expressed in the early embryo but becomes restricted to the lymphatic endothelial a latter stage of development. It is important for lymphangiogenesis.

Gen-ID: 2324

NCBI Accession: NM_002020, NP_002011

UniProt: P35916

Pathways: RTK Signalweg, Signaling Events mediated by VEGFR1 and VEGFR2, VEGF Signaling